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Abstract
Landmark studies such as the Bogalusa Heart study, Pathobiological Determi-
nants of Atherosclerosis in Youth study, and Muscatine and Young Finns studies
established that the atherosclerotic process begins in childhood. Early precursors of
atherosclerosis may increase risk of cardiovascular morbidity in adulthood. Follow-
up studies of children with familial homozygous hypercholesterolemia showed that
initiation of statin therapy slowed the progression of carotid intima-media thickness
and reduced cardiovascular disease risk. Despite the growing evidence on the effi-
cacy of statins and a rising prevalence of dyslipidemia, there are concerns regarding
long-term safety and efficacy. Moreover, data on statin use in children with sec-
ondary dyslipidemia are sparse. This chapter provides a comprehensive review of
the current state of literature on the indications, contraindications, efficacy and
safety data on the use of statins in pediatric dyslipidemia.
Keywords: pediatric dyslipidemia, HMG Co-A reductase inhibitors, low-density
lipoprotein cholesterol, cardiovascular risk factors
1. Introduction
Cardiovascular disease (CVD) is the leading cause of mortality in the United
States [1]. Atherosclerosis, a silent precursor of CVD has its origins from early in
childhood [2, 3]. Some dyslipidemias such as familial hypercholesterolemia (FH)
and familial combined hyperlipidemia (FCH) are highly prevalent clinically silent
disorders. Elevated lipid levels in childhood track well into adulthood [4]. In 2011,
the National Heart, Lung, and Blood Institute (NHLBI) convened an expert panel
on Cardiovascular Health and Risk Reduction in Children and Adolescents, which
recommended for universal lipid screening in the pediatric population [5]. The
universal lipid screening leads to identification of a large number of children with
previously unrecognized dyslipidemia. Statins are one of the most potent classes
of lipid lowering medications for CV risk reduction. This chapter describes the
current screening and management guidelines, efficacy and adverse effects of
statin therapy in pediatric dyslipidemia.
1.1 Mechanism of action of statins
The primary mechanism of action of statins is inhibition of the enzyme-
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This is a rate-
limiting step in the biosynthesis of cholesterol. Reduced intrahepatic cholesterol
leads to decreased VLDL assembly. The hepatocyte cholesterol depletion leads to
upregulation of sterol regulatory binding element proteins (SREBPs), the nuclear
transcription factors that regulate LDL receptors (LDL-R). Upregulation of LDL-R
1
on the surface of the hepatocyte in turn results in increased uptake and degradation
of low-density lipoprotein cholesterol (LDL) [6]. They reduce the secretion of
apoB, which affects the rate at which HMG CoA reductase is available to synthesize
cholesterol again [7].
Statins induce inhibition of the Rho-signaling pathway, activate peroxisome
proliferator-activated receptor alpha (PPARα) and improve HDL levels by
increased production of apoA-I, the major apolipoprotein of HDL [8, 9]. Decrease
in isoprenylation of signaling molecules, such as Ras, Rho, and Rac, leads to the
modulation of various signaling pathways. By inhibiting mevalonic acid synthesis,
statins prevent the synthesis of isoprenoid intermediates farnesyl pyrophosphate
and geranyl geranylpyrophosphate [10]. It has been long established that a pro-
inflammatory environment is necessary for plaque progression and advancement
of atherosclerosis, and these intermediates are known to have a pro-inflammatory
effect. Statins can inhibit posttranslational modification of Ras and Rho, which
regulate cell proliferation, differentiation, apoptosis, and the cytoskeletal modifica-
tions [11]. Statins have also been proposed to be beneficial to prevent progression
of atherosclerosis by their pleiotropic effect [12]. Experimental models have
suggested reduction in T-cell clustering with the use of statins, thereby proposing
an immunomodulatory effect [13].
1.2 Risk factors and medical conditions
Table 1 lists the medical risk factors and conditions to be considered while
screening for dyslipidemia as defined by the Expert Panel on Integrated Guidelines
for Cardiovascular Health and Risk Reduction in Children and Adolescents. The
terminology from this table will be used throughout the chapter.
1.3 Current screening recommendations for pediatric dyslipidemia
Although the atherosclerotic process begins in childhood, most pediatric lipid
disorders do not have any obvious clinical manifestations [2, 3]. Screening based on
family history alone can miss up to 30–60% dyslipidemias [5, 14]. In higher risk
Positive family history: parent, grandparent, aunt, uncle, sibling with any of these before the age 55 Y
in a male or 65 Y in a female: myocardial infarction, stroke, angina, coronary artery bypass, stent,
angioplasty, sudden cardiac death, parent with total cholesterol >240 mg/dL
High risk factors:
• Hypertension requiring drug therapy (BP ≥ 99th%
ile + 5 mmHg)
• Current cigarette smoker
• BMI ≥ 97th%ile
Moderate risk factors:
• Hypertension not requiring drug therapy
• BMI ≥ 95th%ile, < 97th%ile
• HDL–C < 40 mg/dL
High risk medical conditions:
• Diabetes mellitus, type 1 and type 2
• Chronic renal disease/end-stage renal disease/
postrenal transplant
• Postorthotopic heart transplant
• Kawasaki disease with current aneurysms
Moderate risk medical conditions:
• Kawasaki disease with regressed coronary
aneurysms
• Chronic inflammatory disease
• Human immunodeficiency virus (HIV)
infection
• Nephrotic syndrome
Abbreviations: BP, blood pressure; BMI, body mass index.
Adapted from Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and
Adolescents, National Heart, Lung, and Blood Institute 2011.
Table 1.
Cardiovascular risk factors and high-risk medical conditions.
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adult patients, especially those with disorders such as FH, statin therapy has been
retrospectively associated with reducing risk of major cardiovascular events [15]. In
the absence of clear history or physical examination findings, recognition of chil-
dren with lipid disorders needs universal screening. The United States NHLBI, the
American Academy of Pediatrics and the American Heart Association have all
endorsed selective risk based screening and universal screening [5, 16, 17]. Interna-
tional Organizations such as the European Atherosclerosis Society recommend
selective and cascade screening [18]. In contrast, the United States Preventive
Services Task Force (USPSTF) concluded that current evidence is insufficient to
assess the benefits or harms of screening for lipid disorders in children and adoles-
cents, even though it acknowledges the importance of early identification of
dyslipidemias [19]. For many CV risk factors like dyslipidemia, hypertension, and
obesity, it is difficult to conduct large, long-term studies because of the time, cost
and expected difficulties in study adherence. Recently, relatively long term follow
up studies indicated that the initiation of statin therapy during childhood in patients
with FH slowed the progression of carotid intima-media thickness and reduced the
risk of cardiovascular disease in adulthood [20].
Screening can be performed either with a fasting or non-fasting serum lipid
profile. The triglyceride (TG) levels are the most affected component of the lipid
profile by non-fasting status. The LDL and non-HDL (TC-HDL) are mostly unaf-
fected by the non-fasting status and can therefore be used for screening purposes
[21, 22]. Cholesterol and LDL tend to increase until 2 years and plateau until
adolescence. A 10–20% reduction of TC and LDL occurs in both normal children as
well as children with genetic dyslipidemias during puberty, and can result in false
negatives during this time [23]. Therefore, it is important to universally screen for
lipid disorders between ages 9–11 Y and repeat between ages 17–19 Y. Table 2
depicts lipid values very by age, according National Cholesterol Education Program
(NCEP) Expert Panel on Cholesterol Levels in Children.
Up to 12 months, no routine screening of lipid profiles is recommended in
infancy. Between 2 and 8 Y and 12 and 16 Y, a fasting lipid profile (FLP) is
recommended if there is a positive family history, if the child has a moderate or
high-risk medical condition or a high risk factor. Between 9 and 11 Y and 17 and
21 Y, universal screening is recommended. If on a non-fasting sample, the non-
HDL ≥ 145 mg/dL or HDL < 40 mg/dL, it is recommended to repeat an FLP twice
within 2 weeks to 3 months and average the results. Values to address on the FLP
Categories Acceptable Borderline high High
Total cholesterol <170 171–199 >200
LDL <110 110–129 ≥130
Non-HDL <120 120–144 ≥145
TG (0–9 Y) <75 75–99 ≥100
TG (10–19 Y) <90 90–129 ≥130
HDL >45 40–45 <40
Abbreviations: TC, total cholesterol; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein
cholesterol; TG, triglyceride.
Values from the National Cholesterol Education Program [24]. All fasting values in mg/dL. To convert to SI units,
divide total cholesterol, LDL, HDL, and non-HDL by 38.6, and for TG, divide by 88.6.
High and borderline-high values are indicative of approximately the 95th and 75th percentiles for age.
Table 2.
Lipid values by age.
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after averaging the results include LDL ≥ 130 mg/dL, non-HDL ≥ 145 mg/dL, HDL
< 40 mg/dL, TG ≥ 100 mg/dL if <10 years; ≥ 130 mg/dL if ≥10 years [5].
1.4 Diagnostic considerations in pediatric dyslipidemia
Dyslipidemia could be primary or secondary. Primary lipid disorders include
monogenic conditions like FH or familial hypertriglyceridemia. Some genetic
dyslipidemias like FCH do not have a recognized genetic defect yet, and have
variable degrees of dyslipidemia and varying patterns of increase of TG and LDL
within the same family. Obesity can exacerbate the expression of dyslipidemia in
children with this underlying genotype. Lipid disorders could also be secondary to
the underlying untreated medical conditions. Some considerations include diabetes
mellitus, hypothyroidism, hypercortisolism, metabolic syndrome, growth hormone
deficiency, pregnancy, drug and medication use, acute and chronic hepatitis,
nephrotic syndrome, chronic kidney disease etc. [25–31].
After ruling out secondary dyslipidemias, primary dyslipidemias are to be con-
sidered. Primary lipid disorders can be broadly categorized by the predominantly
affected component of the lipid profile. Table 3 depicts patterns of inheritance,
predominant affected lipoprotein and prevalence in the more commonly encoun-
tered primary dyslipidemias. Of these conditions, the most prevalent conditions are
heterozygous FH (HeFH 1:300) and FCH (1:100).
1.5 Lifestyle management of dyslipidemia
Dietary management and lifestyle changes are the cornerstone of therapy for
many secondary dyslipidemias. A registered dietitian nutritionist is central to
implementing lifestyle changes, trained to assess the child’s nutritional status and
make practical modifications to facilitate behavioral changes. In children and ado-
lescents with obesity, moderate, gradual weight reduction has been shown to
improve dyslipidemia and decrease insulin resistance.
The NCEP has proposed a stepwise dietary regulation for children with elevated
LDL levels. For all children more than 1 year of age and older, the Cardiovascular
Health Integrated Lifestyle Diet (CHILD)-1 diet is the first step (Step 1 diet); this
constitutes total fat (25–30% of total daily calories), saturated fat (8–10% of daily
kcal/estimated energy requirements), avoiding trans-fat, <300 mg/day from cho-
lesterol, dietary fiber (14 g/1000 kcal), fat-free unflavored milk, limiting sodium
intake and sweetened juice (no added sugar) <120 mL/day. Polyunsaturated fatty
acids up to 10% of daily calories, and monounsaturated fatty acid intake of 10–15%
of daily caloric intake is recommended [5].
If the CHILD-1 modifications do not show the desired lipid changes within
3 months of initiation, the next step is to advance to the CHILD-2 diet (Step 2 diet),
which further restricts saturated fat. The CHILD-2 diet consists of 25–30% of total
calories from fat, <7% from saturated fat, <10% from monounsaturated fat, and
avoiding trans-fat. The CHILD-2 diet specific for LDL lowering (CHILD-2-LDL)
also recommends use of fiber supplementation and plant stanols/sterols: plant sterol
and stanol esters up to 2 g/day, water-soluble fiber psyllium, dose of 6 g/day
(2–12 years) and 12 g/day (>12 years). The CHILD 2 diet specific to TG lowering
(CHILD-2-TG) recommends decreasing sugar and sugar-sweetened beverages,
replacing simple with complex carbohydrates, and increasing dietary fish to
increase omega-3 fatty acid intake [5].
The expert panel also recommends at least 1 h of moderate-to vigorous physical
activity every day of the week, with vigorous, intense physical activity on at least 3
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of these days in agreement with the 2008 Physical Activity Guidelines for Americans
from the U.S. [5].
1.6 Laboratory evaluations prior to statin therapy
Suggested serum testing prior to initiation of statin therapy include testing to
rule out secondary causes of dyslipidemia—serum albumin, blood glucose level or
Name Genetic defect Pattern of
inheritance
Incidence Lipid profile/lipoprotein
pattern
Disorders with elevated LDL
Familial homozygous
hypercholesterolemia
LDL-R
Gain of function
PCSK9
Familial defective
apo B-100
AD 1:1,000,000 ↑↑↑ TC
↑↑ LDL
Familial heterozygous
hypercholesterolemia
Same as above AR 1:300–400 ↑ TC↑ LDL
Autosomal recessive
hypercholesterolemia
LDL-R
Adaptor protein
AR
<1:1,000,000
↑ TC↑ LDL
Sitosterolemia ABCG5
ABCG8
AR
<1:1,000,000
↑ TC↑ LDL
↑ serum sitosterol, campesterol
Lysosomal acid lipase
deficiency
LIPA gene defect AR 1:40,000–
300,000
↑ LDL
Cholesterol 7α-
Hydroxylase deficiency
CYP7A1 gene Semi-
dominant <1:1,000,000
↑ TC↑ LDL↑TG
Familial combined
hyperlipidemia
Unknown AD 1:100–200 ↑ TC↑ LDL↑VLDL↑TG,
Chylomicrons,↑ VLDL
remnants
Dysbetalipoproteinemia apoE AR 1:5000 ↑↑ TC↑↑ LDL↑↑ IDL
↑↑ TG↑ Chylomicrons
Disorders with elevated TG
Familial
hypertriglyceridemia
Unknown AD 1:500 ↑ TC↑↑ TG
Familial chylomicronemia LPL deficiency
apoC-II deficiency
apoA5 and
GPIHBP1 loss-of-
function
AR 1 out of
1,000,000
↑ TC↑↑↑ TG
Disorders with reduced HDL
Hypoalphalipoproteinemia APOA1 AD
<1:1,000,000
↓ HDL↓ or normal TG
Tangier disease ABCA1 AR
<1:1,000,000
↓ HDL normal or↑ TG
Lecithin cholesterol acyl
transferase deficiency
LCAT (16q22.1) AR
<1:1,000,000
↓ HDL
Abbreviations: TC, total cholesterol; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; TG,
triglyceride; AD, autosomal dominant; AR, autosomal recessive; LDL-R, LDL receptor; PCSK9, proprotein convertase
subtilisin/kexin type 9; apoB, apolipoprotein; ABCG, ATP-binding cassette sub-family G member; LIPA, lysosomal acid lipase
type A; LPL, lipoprotein lipase; GPIHBP1, glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1;
LCAT, lecithin cholesterol acyl transferase.
Table 3.
Characteristic features of primary dyslipidemias.
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hemoglobin A1C, renal function tests, serum thyroid-stimulating hormone, free T4
concentration, and a pregnancy screen. These tests are to be done as deemed
clinically necessary. Liver function studies, serum creatinine kinase (CK) levels are
useful to obtain at baseline to monitor for future potential adverse effects.
1.7 Indications for statin therapy in pediatrics
Children with average LDL-C ≥ 190 mg/dL have a high likelihood of FH and
almost certainly require pharmacotherapy, as diet and exercise modifications can
maximally reduce lipids by 10–20% [32]. Fasting TG level of ≥500 mg/dL (which
may indicate postprandial elevations to >1000 mg/dL and risk of pancreatitis) are
also best referred and managed by a lipid specialist. Referral may ultimately be
required if LDL levels remain elevated beyond ≥160 mg/dL despite 6 months of
lifestyle interventions. Once the lipid profile has been repeated within a 2 week to
3-month period, the following average values currently are recommended to start
statin therapy concomitantly with diet and lifestyle modifications.
In children <10 years of age:
• Homozygous familial hypercholesterolemia (HoFH) with LDL typically above
400 mg/dL
• CVD within the first two decades of life/post cardiac transplantation
• LDL ≥190 mg/dL + positive family history, OR 1 high risk factor/condition, OR
2 moderate risk factors/conditions
In children ≥10 years:
• LDL ≥ 190 mg/dL
• LDL ≥ 160 mg/dL + positive family history, OR 1 high risk factor/condition,
OR 2 moderate risk factors/conditions
• LDL ≥130 mg/dL + 2 high risk factors/conditions, OR 1 high risk factor/
condition and 2 moderate risk factors/conditions, OR clinical CVD
1.8 Expected effects of statin therapy
Aside from PCSK9 inhibitors, statins are the most potent class of lipid
lowering agents. The expected effects of statin therapy on TC and LDL levels are
dependent on their potency and dosing. Most statins have a mild effect on
increasing HDL by 2–5%, and on decreasing TG levels by up to 40%. Table 4
outlines the starting dosing, properties and potency by expected effects on LDL
reduction of some of the commonly used statins in pediatrics. Although the statins
with longer half-lives inhibit the enzyme for a longer time, even with statins that
have a shorter half-life are effective at reducing the LDL levels because they reduce
overall serum levels of lipoproteins with a half-life of approximately 2–3 days. For
this reason, all statins can be administered in once a day dosing. The general
principal behind statin therapy in pediatrics is to use the lowest effective doses of a
statin. Currently, the maximum daily dose studied in pediatrics is for 40 mg of
lovastatin, pravastatin, and simvastatin; 20 mg of atorvastatin and rosuvastatin; and
80 mg of fluvastatin.
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In the United States, pravastatin and pitavastatin have FDA approval for chil-
dren age ≥ 8 years with HeFH. Lovastatin, simvastatin, fluvastatin, atorvastatin and
rosuvastatin have been approved for children ≥10 years with FH. At the higher
prescribed doses, atorvastatin and rosuvastatin are more potent than the other
approved medications [33]. Key randomized clinical trials for each of these statins
in the order of approval for pediatric use are summarized in Table 5.
1.9 Special considerations for high-risk conditions
As diabetes is considered a CV risk factor, intensive lipid management is
suggested for these patients. In addition to maintaining the best glycemic control
possible, the American Diabetes Association recommends starting treatment with
statins for LDL ≥ 160 mg/dL and considering treatment for LDL ≥ 130 mg/dL with
additional risk factors basing the treatment decision on the child’s complete CVD
risk profile, including assessment of blood pressure, family history, and smoking
status with a goal of lowering LDL to under 100 mg/dL [48].
In nephrotic syndrome, chronic kidney disease and polycystic ovarian syndrome
as well LDL ≥ 160 mg/dL maybe a threshold for initiating statin treatment in
addition to adequate mediation therapy for the underlying condition, lifestyle and
diet therapy. In Kawasaki disease, patients >2 years old without persistent
coronary artery abnormalities should undergo lipid screening 1 year after the
acute phase, and if normal, universal screening can be considered. Patients with
coronary artery aneurysms should undergo annual screening and treated for
levels ≥160 mg/dL.
1.10 Challenges in pediatric dosing
Thus far, statins are only available in pill form. With the exception of simva-
statin oral suspension, other liquid preparations or flavoring are not readily avail-
able which maybe an issue for children with sensory issues or difficulty swallowing
a pill. A disintegrating formulation of simvastatin is available, and this may be
helpful in younger children. Although compounding the medication at local phar-
macies is an option, several logistical issues limit this accessibility. Some of the
extended release preparations such as Lovastatin and fluvastatin are rarely used in
children, and should not be crushed. Fluvastatin is available as a capsule but the
contents are not to be separated per manufacturer’s instructions.
Statin Typical
dose (mg)
Maximum
dose (mg)
Half-
life (h)
Lipophilicity Fecal
excretion
(%)
Renal
excretion
(%)
Effect on LDL
reduction (%)
Atorvastatin 5–10 80 15–30 Lipophilic >98 <2 38–54
Fluvastatin 20 80 0.5–2.3 Lipophilic 93 6 17–33
Lovastatin 10 80 2.9 Lipophilic 83 10 29–48
Pravastatin 5–20 40 1.3–2.8 Hydrophilic 70 20 19–40
Rosuvastatin 5–10 40 19 Hydrophilic 90 10 52–63
Simvastatin 5–10 40 2–3 Lipophilic 60 13 28–41
Abbreviation: LDL, low-density lipoprotein cholesterol.
Table 4.
Starting doses and properties of statin drug therapy.
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Group Study design Test group N Age Condition Duration Outcomes
Atorvastatin
McCrindle et al. [34] Placebo controlled RCT 1020 mg 187 10–17 Y HeFH or severe
hypercholesterolemia
6 months TC↓ 32%
LDL↓ 40%
TG↓ 12%
ApoB↓ 34%
HDL↑ 2.8%
Gandelman et al. [35] No 5–10 mg 39 6–10 Y (TS 1)
10–18 Y (TS 2)
HeFH 8 weeks TC↓ 34.1–35.6%
LDL↓ 40.7–39.7%
TG↓ 6–21.1%
Canas et al. [36] Placebo controlled RCT 10–20 mg 42 10–20Y T1D 6 months TC↓ 21%
LDL↓ 32%
Non-HDL↓ 31%
ApoB↓ 26%
Langslet et al. [37] No 5 mg or 10 mg,
↑ up to 80 mg
272 6–15 Y HeFH 3 years LDL↓ 43.8% TS 1 and
39.9% for TS ≥2
Fluvastatin
Van der Graaf
et al. [38]
No—single arm study 80 mg 85 10–16 Y HeFH 2 years TC↓ 27.1%
LDL↓ 33.9%
TG↓ 5.3%
ApoB↓ 24.2%
Lovastatin
Lambert et al. [39] Controlled multicenter RCT 10, 20, 30 and
40 mg doses
69 <17Y
(boys only)
FH 8 weeks TC↓ 17–29%
LDL↓ 21–36%
ApoB↓ 19–28%
Stein et al. [40] Placebo controlled RCT 10, 20 and 40 mg 132 10–17 Y
(boys only)
HeFH 1 year TC↓ 13, 19 and 21%
LDL↓ 17%, 24 and 27%
TG↓ 4, 8 and 6%
ApoB↓ 23% (in 40 mg/d)
Claus et al. [41] Placebo controlled RCT 20 mg for 4 weeks,
then 40 mg
54 10–17 Y
(girls only)
HeFH 24 weeks TC↓ 17–22%
LDL↓ 23–27%
ApoB↓ 20–23%
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Pravastatin
Knipscheer et al. [42] Placebo controlled RCT 5, 10 and 20 mg 72 8–16 Y FH 12 weeks TC↓ 24.6%
LDL↓ 32.9%
ApoB↓ 26.8%
HDL↑ 10.8%
Rosuvastatin
Avis et al. [43] Placebo controlled RCT 5, 10 and 20 mg 177 10–17 Y FH 52 weeks TC↓ 27.1%
LDL↓ 33.9%
TG↓ 5.3%
ApoB↓ 24.2%
Braamskamp
et al. [44]
Open label multicenter intention to
treat analysis
5–20 mg 197 6–17 Y HeFH 24 months TC↓ 32%
LDL↓ 43%
TG↓ 5%
ApoB↓ 36%
Most adverse events mild
Stein et al. [45] Placebo controlled cross over RCT 20 mg 13 7–15 Y HoFH 24 weeks Reduction of 22.3% LDL on rosuvastatin versus
placebo with apheresis or ezetimibe
Simvastatin
de Jongh et al. [46] Placebo controlled RCT 10–40 mg 50 9–18 Y FH 28 weeks TC↓ 30%
LDL↓ 39.8%
TG↓ 16.7%
FMD improved in simvastatin group
García-de-
la-Puente [47]
Placebo controlled cross over RCT 5–10 mg 25 4–17 Y Hyperlipidemia secondary
to renal disease
6 months TC↓ 23.3.4%
LDL↓ 33.1%
TG↓ 21%
Abbreviations: TC, total cholesterol; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG, triglyceride; apoB, apolipoprotein B; N, number of participants; Y, years; HoFH, familial homozygous
hypercholesterolemia; HeFH, familial heterozygous hypercholesterolemia; FH, familial hypercholesterolemia; RCT, randomized control trial; TS, tanner stage; mg, milligram; T1D,Type 1 diabetes mellitus.
Table 5.
Prominent pediatric clinical trials with lipid lowering effects of statins.
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1.11 Considerations for statin bioavailability
1.11.1 Factors affecting absorption
Recently, ontogenic and genetic factors have been described as potential vari-
ables influencing systemic availability of statins [49]. As statins are orally delivered,
the gastric milieu and intestinal transport can have effects on the efficacy, and may
have population and individual level variability in efficacy. Influx transport pro-
teins such as OATP1A2 and OATP2B1, which are pH dependent, are shown to have
an effect at the level of the enterocyte for absorption of statins [50]. Variations in
MRP2 (ABCC2 c.1446C>G), an efflux transporter has been shown to decrease the
bioavailability of pravastatin [51]. Co-ingesting statins with food has also shown to
have some variability in bioavailability that affects some statins more than others.
For instance, absorption of fluvastatin, pravastatin and rosuvastatin is delayed
when taken with food [52–55]. In contrast, package inserts of lovastatin state that
levels are lower when administered under fasting conditions. Timing of food intake
appears to have no effect on simvastatin.
Timing of administration has also shown to have some effect on bioavailability.
This is due to multiple factors including diurnal cholesterol biosynthesis peak at
nighttime and early morning and possibly the difference in gastric emptying,
absorption and distribution. Reduction in both peak concentration as well as overall
area under the curve (AUC) distribution have been described with evening admin-
istration of pravastatin and atorvastatin [56, 57]. Fluvastatin concentrations have
been reportedly higher when dosed in the evening [58] while rosuvastatin remained
unaffected [59]. Although statins are best given in the evening to coincide with the
peak cholesterol biosynthesis at night, and the long-acting statins, atorvastatin and
rosuvastatin, may be given any time, in clinical practice, the difference in efficacy
in relation to the timing is negligible.
As with most oral medications, first pass metabolism is another factor with the
potential to influence bioavailability and toxicity. Depending upon the statin, when
the enterocyte is the level at which first-pass occurs, the bioavailability may be
reduced, reducing toxicity but overall efficacy as well. If the first pass occurs at the
level of the liver, since the hepatocytes are the primary target for the statins, a more
favorable risk profile is potentially created. If the hepatocytes have more primary
exposure, reduction in systemic availability and increased hepatic exposure should
lead to lesser adverse effects while enhancing action at the target organ level,
creating a more favorable safety profile [60].
1.11.2 Factors affecting metabolism
Of the multiple cytochromes that have been shown to have in-vitro capacity of
metabolizing statins, CYP3A4 has been the most important, especially for simva-
statin, lovastatin, and atorvastatin [61, 62]. Rosuvastatin is able to strongly inhibit
CYP2C9 activity [63]. Clinically, the co-administration of CYP3A4 inhibitors like
clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir,
verapamil, goldenseal, grapefruit, etc. can lead to significant elevations in statin
levels, and have the risk of higher toxicity. Inducers of CYP3A4 including pheno-
barbital, phenytoin, rifampicin, St. John’s Wort and glucocorticoids can reduce the
bioavailability of statins [64].
While considering drug interactions, concomitant administration of other lipid
lowering therapy has to be kept in mind, especially for treatment of conditions such
as FCH. For instance, gemfibrozil, which is used to lower TG levels, can engage
with the OATP1B1-mediated transport of the statin into the hepatocyte and gut
10
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cells. It can also catalyze glucuronidation. The net effect is these interactions are a
higher concentration of systemic statin level and a greater risk of adverse effects
[62, 65].
1.11.3 Factors affecting elimination
Elimination can be significantly impacted by half-lives as mentioned in Table 4.
Some statins including atorvastatin and simvastatin undergo conjugation while
pravastatin, rosuvastatin, and pitavastatin do not undergo extensive conjugation.
Biliary excretion of the UGT-conjugated statins occurs through—multidrug resis-
tance 1 (MDR1; ABCB1), multidrug resistance-associated protein 2 (MRP2;
ABCC2), breast cancer resistance protein (BCRP; ABCG2), bile salt exporting
pump (BSEP; ABCB11) [60]. Although these efflux transporters have had in vitro
effects, the in vivo effects of variants of these transporters are not well studied.
Renal clearance is less significant than the biliary elimination of statins [55, 66, 67].
Of the statins, pravastatin is the most renally cleared at around 20% [68].
1.12 Adverse effects of statin therapy
Of all the classes of lipid lowering medications, statins are best tolerated with
least reported adverse events [69]. The safety profile of statins has been well studied
in adults. Most studies studying the safety and efficacy of statins are in children
with FH. The most commonly reported side effects including muscle related
adverse events and hepatic transaminase occur relatively infrequently. When statin
treatment was starting to be recommended as young as 8 years of age, there were
fair concerns about the effects on cognition, growth and development, metabolic
rate with potential for decades of exposure to this medication.
Multiple studies have shown no adverse effects of statins on growth and sexual
maturation [70]. In addressing the overall safety profile of statins, a recent meta-
analysis showed that statin treatment was effective for treating FH, with a good
short-term safety profile [69]. The 10- and 20-year follow-up studies on the use of
statins in pediatric dyslipidemias did not report significant serious adverse events
[20, 71]. There is a dearth of large long-term randomized controlled trials to estab-
lish the long-term safety issues of statins.
1.12.1 Rhabdomyolysis/myopathy
Lipophilic statins are more prone to causing myopathy as they attain greater
intramuscular concentrations compared to hydrophilic statins. Pravastatin and
rosuvastatin are hydrophilic, others are lipophilic. However, fluvastatin, a lipophilic
statin has reportedly lower side muscle-related side effects. Non-specific muscle
aches and weakness has been described with all the statins. An extensive systematic
review on statin safety in adults determined rhabdomyolysis to be rare at 3 per
100,000 person-years for atorvastatin, simvastatin, lovastatin, pravastatin, and
fluvastatin [72]. In children, three large systematic reviews did not find any differ-
ence between the statin group and control group for rhabdomyolysis (CK levels
increased 10 fold from upper limit of normal) [69, 73, 74]. Clinically important
rhabdomyolysis is evidence of muscle cell destruction or enzyme leakage, regardless
of the CK level, considered to be causally related to a change in renal function. In
practice, when CK levels are up trending and elevated to >10 upper limit of normal,
with or without co-existent myoglobinuria and/or renal injury, it is recommended
to stop the statin [75]. Given that this is a rare side effect, common causes including
exercise, cold exposure, trauma, seizures, hypothyroidism, recent infections/myositis,
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autoimmune etiologies etc. need to be considered. Therapy can be commenced,
preferably with a different statin when the CK levels normalize.
Statin induced myopathy is exceedingly rare in children with FH. In adults,
myopathy, which includes myalgia and an increase in serum CK levels, occurs in
approximately 0.1–1% of patients using statins. The risk factors associated with this
are concomitant renal insufficiency, hepatic dysfunction, hypothyroidism,
polypharmacy and intake of CYP3A4 inhibitors [76]. Of the reported cases, a co-
existent polymorphism in SLCO1B1 resulting in decreased transport of statins into
the hepatocytes, thereby increasing systemic toxicity was discovered, especially with
lipophilic statins like simvastatin. Statin induced myopathy was 4.5 and 16.9 times
more likely in heterozygote and homozygote carriers with this polymorphism [77].
1.12.2 Hepatic dysfunction
This is a rare side effect in statins, and in adult studies, the overall incidence of
persistent transaminase elevation is considered to be about 0.5–3%. The Scandina-
vian Simvastatin Survival Study as well as the Heart Protection Study Collaboration
group, as well as the Air Force/Texas Coronary Atherosclerosis Prevention Study,
which were large randomized trials that studied simvastatin and lovastatin in large
populations did not find significant differences in persistent hepatic transaminases
between statin and placebo therapy in adults [78–80]. In children, three large
systematic reviews did not find any difference between the statin group and control
group for incidence of transaminitis (over 3-fold increase in alanine transferase or
aspartate aminotransferase) [69, 73, 74].
Previously, patients receiving statins routinely measured liver function studies
for monitoring transaminase elevation. In 2012, the FDA withdrew this require-
ment, and in practice, liver enzymes are measured as clinically needed. The exam-
iner should inform the patient/parent to report symptoms of jaundice, malaise and
fatigue as a sign of potential hepatotoxicity. In practice, if transaminase levels are
found to be greater than 3 times the baseline either in symptomatic patients or
during routine evaluation, the test should be repeated and other etiologies ruled out
as well, given the rare incidence. During the work up process, one should consider
discontinuation or dose reduction based on the presentation. Currently, the benefit
of statin therapy far outweighs the risk of liver- and muscle-related adverse events.
1.12.3 Teratogenicity/need for contraception
Traditionally, animal studies have shown the potential of teratogenicity with
statins due to disruption of cholesterol synthesis [81, 82]. Human studies in this
regard are lacking, and the data we have so far is derived mostly from small cohort
studies and case reports [83]. Contrastingly, some cohort studies did not find a
significant teratogenic effect from maternal use of statins in the first trimester [84].
A meta-analysis of 6 controlled studies including a total of 618 women failed to find
an increase in the risk of birth defects [85]. Many of these studies, however, were
small, short term and insufficiently powered, making it difficult to generalize the
results. At this time, women of childbearing age, as well as pubertal girls should be
advised about concerns of teratogenicity with statin use in pregnancy, and
counseled on the importance of concomitant contraceptive use.
1.12.4 Risk of type 2 diabetes mellitus (T2DM)
One of the concerning long-term side effects of statin treatment in children has
been the higher risk of developing T2DM. A meta-analysis of RCTs in 91,000
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adult patients showed that statin therapy was associated with a 9% increase in the
incidence of T2DM. Although there was a slightly increased risk of development of
diabetes, the absolute risk as well as the comparative risk when measured against
risk of coronary risk reduction was low [86]. In contrast, other studies in patients
with FH treated with statins did not show a higher risk [87]. In pediatrics, the
available data have been mostly reassuring, with two large 10- and 20-year follow-
up studies not showing a significant increase in the incidence of T2DM when
compared to the general population incidence [20, 71].
1.12.5 Concerns for non-specific effects on reduced cholesterol synthesis
Cholesterol is utilized by ubiquitously, and has a number of biological functions
in other cells in the body; therefore, many non-hepatic cells also are capable of
synthesizing LDL-R for uptake of cholesterol. Cholesterol is a precursor for both
steroid and sex hormones. However, the use of statins has not been associated with
adverse effects on the production of hormones that depend on normal sterol level
availability, for instance, the adrenal hormones [74]. Fetal and neonatal cholesterol
levels are lower, suggesting that an optimal homeostatic mechanism exists in which
even during periods of high metabolic demand, lower levels of cholesterol are
sufficient to support normal biological function [88]. Although some variations in
dehydroepiandrosterone sulfate (DHEAS) and luteinizing hormone (LH) levels are
reported in the literature, these differences were too small to have clinical rele-
vance, given that the studied children did not have any growth or pubertal abnor-
malities [74].
2. Conclusions
Pediatric dyslipidemia could be due to monogenic, secondary or polygenic
causes. Fatty plaques, the precursors of atherosclerosis and exposure to cardiovas-
cular risk factors begin in childhood and progress into adulthood. All children with
dyslipidemia benefit from diet and lifestyle modifications but the effect is limited
in children with markedly elevated LDL levels. Statins are first line pharmaco-
therapeutic agents for elevated LDL concentrations with a favorable safety profile
and robust short-term data with benefits outweighing the risks. Long-term data
are needed in children to better understand the safety and efficacy of these
medications.
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Appendices and nomenclature
BP blood pressure
BMI body mass index
TC total cholesterol
LDL low density lipoprotein cholesterol
HDL high density lipoprotein cholesterol
TG triglyceride
AD autosomal dominant
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AR autosomal recessive
LDL-R LDL receptor
NHLBI National Heart Lung and Blood Institute
NCEP National Cholesterol Education program
USPSTF United States Preventive Services Task Force
HoFH familial homozygous hypercholesterolemia
HeFH familial heterozygous hypercholesterolemia
FCH familial combined hyperlipidemia
HMG-CoA reductase 3-hydroxy-3-methylglutaryl-coenzyme A reductase
PCSK9 proprotein convertase subtilisin/kexin type 9
apoB apolipoprotein
ABCG ATP-binding cassette sub-family G member
LIPA lysosomal acid lipase type A
LPL lipoprotein lipase
GPIHBP1 glycosylphosphatidylinositol anchored high density lipo-
protein binding protein 1
LCAT lecithin cholesterol acyl transferase
CVD cardiovascular disease
CK creatinine kinase
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